Aligos Therapeutics to Present Nonclinical and Clinical Data for its Chronic Hepatitis B and NASH Portfolio at AASLD’s The Liver Meeting® 2022

October 21, 2022

https://www.globenewswire.com/news-release/2022/10/21/2539322/0/en/Aligos-Therapeutics-to-Present-Nonclinical-and-Clinical-Data-for-its-Chronic-Hepatitis-B-and-NASH-Portfolio-at-AASLD-s-The-Liver-Meeting-2022.html

SOUTH SAN FRANCISCO, Calif., Oct. 21, 2022 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq:ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced seven upcoming poster presentations at The Liver Meeting® (November 4-8, 2022), hosted by the American Association for the Study of Liver Diseases (AASLD).

Read more at globenewswire.com

Related news for (ALGS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.